ImmunoGen Target of Unusually Large Options Trading (NASDAQ:IMGN)

ImmunoGen, Inc. (NASDAQ:IMGN) saw some unusual options trading activity on Wednesday. Investors purchased 11,883 call options on the stock. This is an increase of 1,287% compared to the typical daily volume of 857 call options.

Shares of ImmunoGen stock opened at $5.80 on Thursday. The firm has a market capitalization of $1.17 billion, a PE ratio of -20.00 and a beta of 1.33. The firm’s 50 day moving average is $5.77 and its 200 day moving average is $6.32. ImmunoGen has a 1 year low of $4.97 and a 1 year high of $10.88.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, July 30th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. The company had revenue of $16.90 million for the quarter, compared to analyst estimates of $18.92 million. ImmunoGen had a negative net margin of 40.82% and a negative return on equity of 106.62%. ImmunoGen’s revenue for the quarter was up 12.7% compared to the same quarter last year. As a group, equities research analysts predict that ImmunoGen will post -0.73 EPS for the current year.

Several institutional investors have recently made changes to their positions in the stock. Marshall Wace North America L.P. bought a new stake in ImmunoGen during the 1st quarter worth approximately $52,000. Acadian Asset Management LLC bought a new stake in ImmunoGen during the 1st quarter worth approximately $95,000. UBS Group AG grew its holdings in ImmunoGen by 1,339.1% during the 1st quarter. UBS Group AG now owns 230,543 shares of the biotechnology company’s stock worth $1,867,000 after acquiring an additional 214,523 shares during the last quarter. Geode Capital Management LLC grew its holdings in ImmunoGen by 15.4% during the 1st quarter. Geode Capital Management LLC now owns 3,516,791 shares of the biotechnology company’s stock worth $28,486,000 after acquiring an additional 470,188 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in ImmunoGen by 231.7% during the 1st quarter. Citigroup Inc. now owns 611,917 shares of the biotechnology company’s stock worth $4,957,000 after acquiring an additional 427,428 shares during the last quarter. 89.18% of the stock is currently owned by institutional investors.

ImmunoGen Company Profile

ImmunoGen, Inc engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Recommended Story: What is the quiet period?

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.